Clinical trials: Polymyalgia Rheumatica, active
Polymyalgia Rheumatica
Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica
This is a randomized, double-blind, placebo-controlled, parallel-group, Phase 3, 3-arm study to assess whether treatment with sarilumab at either 150 mg q2w (once every two weeks) or at 200 mg q2w, each given with a 52-week…
- Trial name
- ZIRCON (NCT07286214)
- Testing
- Sarilumab
- Where
- 85 sites in United States, Austria and 8 more
- Volunteers
- 300 people
- Sponsor
- Sanofi
Polymyalgia Rheumatica
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.
- Trial name
- REPLENISH-EXT (NCT06331312)
- Testing
- Secukinumab
- Where
- 85 sites in United States, Argentina and 20 more
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals
Polymyalgia Rheumatica (PMR)
Using Personalized Rehabilitation to Reduce Disease and Increase Activity of Patients With Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is a condition that causes joint pain and stiffness, making it hard for people to do everyday tasks.
- Trial name
- NCT07749547
- Testing
- Movement Pattern Training (MoveTrain), Usual Care
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Arthritis, Polymyalgia Rheumatica
A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy
To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
- Conditions
- Arthritis, Polymyalgia Rheumatica, Immune Checkpoint Inhibitors
- Trial name
- NCT06647134
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Polymyalgia Rheumatica (PMR)
Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica
Polymyalgia rheumatic (PMR) is an inflammatory rheumatic disease affecting the elderly. The diagnosis is based on established ACR/EULAR classification criteria.
- Trial name
- JADORE-BARI (NCT07279688)
- Testing
- Baricitinib 4 MG Oral Tablet, Baricitinib 2 MG Oral Tablet
- Where
- 23 sites in France
- Volunteers
- 140 people
- Sponsor
- University Hospital, Brest
Polymyalgia Rheumatica (PMR)
DNA Methylation in PMR
Polymyalgia Rheumatica (PMR) is treated with corticosteroids; however, long-term treatment is not feasible due to side effects. Withdrawal of corticosteroids causes a subset of patients to relapse, and there is no current way to…
- Trial name
- NCT07748195
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Rheumatic Disease
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating…
- Trial name
- NCT07138898
- Testing
- Methotrexate, Sulfasalazine, Hydroxychloroquine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- NYU Langone Health
Polymyalgia Rheumatica
Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE)
The primary objective of the study is to evaluate the efficacy of olokizumab (OKZ) 64 mg administered subcutaneously every 2 weeks compared with placebo in participants with polymyalgia rheumatica (PMR).
- Trial name
- NCT07670546
- Testing
- Olokizumab
- Where
- 20 sites in Russia
- Volunteers
- 125 people
- Sponsor
- R-Pharm International, LLC
Inflammatory Rheumatism, Polymyalgia Rheumatica
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
To date, there is no available tool that allows, at individual level, determination of the probability to develop clinically relevant complications of prolonged glucocorticoid therapy.
- Conditions
- Inflammatory Rheumatism, Polymyalgia Rheumatica, Giant Cell Arteritis, Idiopathic Inflammatory Myopathies
- Trial name
- PRODIGIOUS (NCT04664465)
- Where
- 12 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Brest
Polymyalgia Rheumatica, Inflammatory Rheumatism
Justification of the Initial Diagnosis and Evaluation of the Overall Evolution of a Cohort of Recent Polymyalgia Rheumatica (JADORE)
Pseudo-rheumatoid arthritis (PRA) is a common inflammatory rheumatic disease of the elderly, characterized by inflammatory shoulder and/or hip pain.
- Trial name
- JADORE (NCT07132164)
- Testing
- biobank sample collection
- Where
- 30 sites in France
- Volunteers
- 400 people
- Sponsor
- University Hospital, Brest
Adrenal Insufficiency, Polymyalgia Rheumatica
Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency
In this double-blinded randomised placebo-controlled clinical trial, the aim is to determine the effect of supplemental hydrocortisone compared with placebo during mild to moderate physical or mental stress on health related…
- Conditions
- Adrenal Insufficiency, Polymyalgia Rheumatica, Giant Cell Arteritis
- Trial name
- RESCUE (NCT05435781)
- Testing
- Hydrocortisone
- Where
- 3 sites in Denmark
- Volunteers
- 250 people
- Sponsor
- Marianne Christina Klose
Rheumatic Diseases, Adult Onset Still Disease
Rheumatology Patient Registry and Biorepository
To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.
- Conditions
- Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT04402086
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Yale University
Giant Cell Arteritis (GCA), Spondylarthritis
Study of the Association Between Sacroiliitis/Axial Spondylarthritis and Giant Cell Arteritis/ Polymyalgia Rheumatica
The purpose of the study is to recruit as many patients as possible presenting with sacroiliitis or authentic axial spondylarthritis and giant cell arteritis.
- Conditions
- Giant Cell Arteritis (GCA), Spondylarthritis, Polymyalgia Rheumatica
- Trial name
- SAGE PPR (NCT07394478)
- Testing
- Description of population
- Where
- 2 sites in France
- Volunteers
- 10 people
- Sponsor
- Hôpital NOVO
Polymyalgia Rheumatica
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse
Polymyalgia rheumatica (PMR) is prevalent among elderly. Untreated, it leads to major reduction in quality of life. Glucocorticoids are the cornerstone of treatment, but have drawbacks, warranting glucocorticoid sparing…
- Trial name
- REDUCE-PMR-2 (NCT05533164)
- Testing
- Rituximab
- Where
- Netherlands
- Volunteers
- 174 people
- Sponsor
- Sint Maartenskliniek
Adrenal Insufficiency, Polymyalgia Rheumatica (PMR)
Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoid Treatment
Cortisol, a glucocorticoid (GC) hormone secreted from the adrenal glands, is essential for survival. Cortisol also possesses anti-inflammatory actions and GC formulations (prednisolone) are used to treat many inflammatory…
- Conditions
- Adrenal Insufficiency, Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA)
- Trial name
- REPLACE (NCT05193396)
- Testing
- Hydrocortisone
- Where
- 3 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Marianne Andersen
Polymyalgia Rheumatica
Treat-to-target Prednisolon Taper in Patients With Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) has an incidence of approximately 1000/10^6 for persons more than 50 years. Treatment with prednisolone carries several significant adverse effects, and it is therefore essential to taper prednisolone…
- Trial name
- NCT05636501
- Testing
- Treat-to-target Prednisolone Taper, Usual care
- Where
- 6 sites in Denmark
- Volunteers
- 120 people
- Sponsor
- Aarhus University Hospital
Polymyalgia Rheumatica (PMR)
Using Novel Imaging to Rethink Diagnostic and Treatment Strategies for Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is the most common chronic inflammatory rheumatic disease among the elderly and is characterized by proximal extremity pain and fatigue.
- Trial name
- REMAP PMR (NCT07010484)
- Testing
- PET/MRI, PET/CT with 18-FDG
- Where
- 7 sites in Denmark
- Volunteers
- 149 people
- Sponsor
- Kresten Krarup Keller
Polymyalgia Rheumatica, Giant Cell Arteritis
Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
Background: Polymyalgia rheumatica (PMR) is characterised by pain of the proximal muscles, general symptoms, and raised inflammatory markers. Treatment with prednisolone has several adverse effects.
- Conditions
- Polymyalgia Rheumatica, Giant Cell Arteritis, Adrenal Insufficiency
- Trial name
- NCT04519580
- Testing
- PET/CT
- Where
- 3 sites in Denmark
- Volunteers
- 98 people
- Sponsor
- Kresten Krarup Keller
Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR)
Pilot Study to evaluateThrombomodulin to Rule Out Giant Cell Arteritis (GCA) in Polymyalgia Rheumatica (PMR) Patients. (THROPIQ)
Polymyalgia rheumatica (PMR) is a rheumatologic condition occurring in patients > 50 years old, characterized by inflammatory pain of the scapular (shoulder) and pelvic (hip) girdles.
- Trial name
- THROPIQ (NCT06609668)
- Testing
- Additional blood samples
- Where
- France
- Volunteers
- 78 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Rheumatic Diseases, Rheumatoid Arthritis (RA)
Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy
The CARe RAiSE project represents a pioneering translational initiative aimed at advancing precision medicine in the treatment of autoimmune rheumatic diseases.
- Conditions
- Rheumatic Diseases, Rheumatoid Arthritis (RA), Giant Cell Arteritis (GCA), Psoriatic Arthritis (PsA)
- Trial name
- CARe RAiSE (NCT07150000)
- Testing
- Ex Vivo Assay
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Bonn